HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS – Free Report) in a report released on ...

Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Surrozen in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now anticipates ...

H.C. Wainwright raised the firm’s price target on Compass Therapeutics (CMPX) to $24 from $10 and keeps a Buy rating on the shares. The company ...

H.C. Wainwright lowered the firm’s price target on I-Mab (IMAB) to $7 from $8 and keeps a Buy rating on the shares. The company continues to ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently ...

Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. As of April 2, 2025, the average one-year price target for ...